1988
The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.
Young R, Longo D, Glatstein E, Ihde D, Jaffe E, DeVita V. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Seminars In Hematology 1988, 25: 11-6. PMID: 2456618.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDoxorubicinEtoposideEvaluation Studies as TopicHumansLeucovorinLeukemiaLeukemia, Radiation-InducedLymph NodesLymphoma, Non-HodgkinMechlorethamineMethotrexateNeoplasms, Multiple PrimaryNeoplasms, Radiation-InducedPalliative CarePrednisoneProcarbazineRandom AllocationVincristineConceptsAdvanced indolent lymphomaLimited radiation therapyTotal nodal irradiationIndolent lymphomaRadiation therapyModality treatmentInitial treatmentAggressive combined modality therapyCombined modality therapyEvaluable patientsInduction therapyInitial therapyNodal irradiationFirst remissionInitial remissionFrequent relapsesMedian durationModality therapySystemic therapyCombination chemotherapyMedian timeHistologic progressionLonger survivalPatient's diseasePatients
1984
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Bakemeier R, Anderson J, Costello W, Rosner G, Horton J, Glick J, Hines J, Berard C, DeVita V. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Annals Of Internal Medicine 1984, 101: 447-56. PMID: 6089632, DOI: 10.7326/0003-4819-101-4-447.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBlood Cell CountCarmustineClinical Trials as TopicCombined Modality TherapyCyclophosphamideFemaleGastrointestinal DiseasesHematologic DiseasesHodgkin DiseaseHumansMaleMechlorethamineNeoplasm StagingPeripheral Nervous System DiseasesPrednisoneProcarbazineRandom AllocationVinblastineVincristineConceptsAdvanced Hodgkin's diseaseHodgkin's diseaseUntreated patientsEastern Cooperative Oncology Group studyDuration of complete remissionRandomized prospective studyTreatment of patientsMOPP regimenHematologic toxicityInduction chemotherapyComplete remissionChemotherapy regimensRemission rateNeurological toxicityProspective studyMOPPRemissionTherapeutic benefitChemotherapyPatientsInduction phaseDiseaseToxicityGroup studyDuration